お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:世界の分子細胞遺伝学市場
市場調査レポート
商品コード
210366

世界の分子細胞遺伝学市場

Molecular Cytogenetics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 468 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.91円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

世界の分子細胞遺伝学市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 468 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の分子細胞遺伝学市場について調査し、市場の動向とセグメント別概要、地域別動向、および市場に参入主要企業のプロファイルと競合動向についてまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 業界概要

  • 分子細胞遺伝学技術:イントロダクション
  • 細胞遺伝学技術に有望な将来的見通し
  • ライフサイエンスの研究開発と医療支出が好ましい環境を作り出す
  • 先進国:主な収益貢献国
  • 途上国の急速な成長見通し
  • 経済的シナリオが促進する市場の拡大

第3章 市場動向、促進因子

  • ラボラトリプロセスにおける分子生物学の重要性
  • 分子生物学技術の進歩
  • アレイベース技術:最大かつ最速で成長する市場セグメント
  • FISHからアレイ技術への移行
  • 次世代シーケンシングが細胞遺伝学プロセスにおける役割を模索
  • 癌の予後にも大きく寄与
  • FISH技術の多様な応用 他

第4章 技術概要

  • 細胞遺伝学の序論
  • 分子生物学の基本的用語と定義
  • 分子細胞遺伝学:定義と範囲
  • 分子細胞遺伝学の応用
  • 技術動向
  • マイクロアレイ技術の探求 他

第5章 競合環境

  • 主要企業
  • 製品上市
  • 近年の業界活動

第6章 世界市場見通し

第7章 地域別市場見通し

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ

第8章 企業プロファイル

目次
Product Code: MCP-6759

Abstract:

Global Molecular Cytogenetics Market to Reach $3.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Molecular Cytogenetics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.1 Billion by 2027, growing at a CAGR of 8.2% over the analysis period 2020-2027. Consumables, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 7.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $483.7 Million, While China is Forecast to Grow at 12.5% CAGR

The Molecular Cytogenetics market in the U.S. is estimated at US$483.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$713.5 Million by the year 2027 trailing a CAGR of 12.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Software & Services Segment to Record 6.9% CAGR

In the global Software & Services segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$225.8 Million in the year 2020 will reach a projected size of US$348 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$431.6 Million by the year 2027, while Latin America will expand at a 8.2% CAGR through the analysis period.

Select Competitors (Total 27 Featured) -

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • Applied Spectral Imaging
  • Bio-Rad Laboratories Inc.
  • Cytognomix Inc.
  • CytoTest Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Leica Biosystems Nussloch GmbH
  • Oxford Gene Technology
  • PerkinElmer Inc.
  • SciGene Corporation
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Molecular Cytogenetics Technologies: An Introductory Prelude
    • Future Prospects Remain Favorable for Cytogenetics Technologies
    • Uptrend in Life Sciences R&D and Healthcare Spending Creates Fertile Environment
    • Northbound Trajectory in Med Tech Sector Generates Parallel Opportunities
    • Developed Regions: Key Revenue Contributors
    • Fast Paced Growth Projected in Developing Regions
    • Prevailing Economic Scenario Favors Market Expansion
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Critical Importance of Molecular Biology in Laboratory Processes: Cornerstone for Present & Future Growth
    • Advanced Molecular Biology Techniques Broaden the Scope of Cytogenetics Technologies
    • Array-based Technologies: Largest & Fastest Growing Market Segment
    • Array-based CGH to Emerge as First Line Test for Clinical Diagnosis of Chromosomal Anomalies
    • Molecular Cytogenetics Find Increasing Penetration in Clinical Pathological Testing
    • Enhanced AP LIS: A Must to Keep Pace with Advancing Molecular Cytogenetic Testing
    • Despite Proliferation of Array-based Methods, FISH Technology Continues to Find Favor
    • Next-Gen Sequencing Seeks Role in Cytogenetics Processes
    • Molecular Cytogenetics Greatly Benefit Cancer Prognosis
    • Increasing Significance of Cytogenetic Analysis in Genetic Disease Diagnosis
    • Proven Efficacy in Nucleic Acid Diagnostics Favors Market Growth
    • Expanding Role of Molecular Cytogenetics in Personalized Medicine
    • Demographics Spell Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for CGH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for FISH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Karyotyping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Clinical & Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: World 15-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 49: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 50: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 52: USA Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 58: USA Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: USA Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: USA 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 61: USA Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: USA Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: USA 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 64: Canada Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 67: Canada Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Canada Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Canada 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 70: Canada Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Canada Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Canada 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 73: Canada Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Canada Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Canada 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 76: Japan Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Japan Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Japan 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 79: Japan Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Japan Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Japan 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 82: Japan Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Japan Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Japan 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 85: Japan Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Japan Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Japan 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 88: China Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: China Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: China 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 91: China Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: China Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: China 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 94: China Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: China Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: China 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 97: China Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: China Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: China 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 100: Europe Current & Future Analysis for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 103: Europe Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Europe Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Europe 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 106: Europe Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Europe 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 109: Europe Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Europe 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 112: Europe Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Europe 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 115: France Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: France Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: France 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 118: France Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: France Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: France 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 121: France Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: France Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: France 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 124: France Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: France Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: France 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 127: Germany Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Germany Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Germany 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 130: Germany Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Germany Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Germany 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 133: Germany Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Germany Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Germany 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 136: Germany Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Germany Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Germany 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 139: Italy Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Italy Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Italy 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 142: Italy Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Italy Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Italy 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 145: Italy Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Italy Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Italy 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 148: Italy Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Italy Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Italy 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 151: UK Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: UK Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: UK 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 154: UK Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: UK Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: UK 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 157: UK Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: UK Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: UK 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 160: UK Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: UK Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: UK 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 163: Spain Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Spain Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Spain 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 166: Spain Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Spain Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Spain 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 169: Spain Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Spain Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Spain 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 172: Spain Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Spain Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Spain 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 175: Russia Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Russia Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Russia 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 178: Russia Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Russia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Russia 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 181: Russia Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Russia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Russia 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 184: Russia Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Russia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Russia 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 187: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Europe Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Europe Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Europe 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 199: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 200: Asia-Pacific Historic Review for Molecular Cytogenetics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 202: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Asia-Pacific Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 205: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Asia-Pacific Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 208: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Asia-Pacific Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 211: Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Asia-Pacific Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 214: Australia Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Australia Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Australia 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 217: Australia Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Australia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Australia 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 220: Australia Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Australia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Australia 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 223: Australia Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Australia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Australia 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 226: India Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: India Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: India 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 229: India Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: India Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: India 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 232: India Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: India Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: India 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 235: India Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: India Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: India 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 238: South Korea Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: South Korea Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: South Korea 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 241: South Korea Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: South Korea Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: South Korea 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 244: South Korea Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: South Korea Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: South Korea 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 247: South Korea Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: South Korea Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: South Korea 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 250: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 256: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 259: Rest of Asia-Pacific Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Rest of Asia-Pacific Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Rest of Asia-Pacific 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 262: Latin America Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 263: Latin America Historic Review for Molecular Cytogenetics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Latin America 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 265: Latin America Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Latin America Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Latin America 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 268: Latin America Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Latin America Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Latin America 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 271: Latin America Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Latin America Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Latin America 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 274: Latin America Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Latin America Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Latin America 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 277: Argentina Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Argentina Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Argentina 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 280: Argentina Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Argentina Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: Argentina 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 283: Argentina Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Argentina Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: Argentina 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 286: Argentina Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Argentina Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: Argentina 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 289: Brazil Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Brazil Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Brazil 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 292: Brazil Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Brazil Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Brazil 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 295: Brazil Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Brazil Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Brazil 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 298: Brazil Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Brazil Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Brazil 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 301: Mexico Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Mexico Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Mexico 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 304: Mexico Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Mexico Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Mexico 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 307: Mexico Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Mexico Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 309: Mexico 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 310: Mexico Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Mexico Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 312: Mexico 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 313: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 314: Rest of Latin America Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 315: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 316: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Rest of Latin America Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 318: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 319: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 320: Rest of Latin America Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 321: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 322: Rest of Latin America Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 323: Rest of Latin America Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 324: Rest of Latin America 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 325: Middle East Current & Future Analysis for Molecular Cytogenetics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 326: Middle East Historic Review for Molecular Cytogenetics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 327: Middle East 15-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 328: Middle East Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 329: Middle East Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 330: Middle East 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 331: Middle East Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 332: Middle East Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 333: Middle East 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 334: Middle East Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 335: Middle East Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 336: Middle East 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 337: Middle East Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 338: Middle East Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 339: Middle East 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 340: Iran Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 341: Iran Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 342: Iran 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 343: Iran Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 344: Iran Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 345: Iran 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 346: Iran Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 347: Iran Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 348: Iran 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 349: Iran Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 350: Iran Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 351: Iran 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 352: Israel Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 353: Israel Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 354: Israel 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 355: Israel Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 356: Israel Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 357: Israel 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 358: Israel Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 359: Israel Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 360: Israel 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 361: Israel Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 362: Israel Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 363: Israel 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 364: Saudi Arabia Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 365: Saudi Arabia Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 366: Saudi Arabia 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 367: Saudi Arabia Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 368: Saudi Arabia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 369: Saudi Arabia 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 370: Saudi Arabia Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 371: Saudi Arabia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 372: Saudi Arabia 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 373: Saudi Arabia Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 374: Saudi Arabia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 375: Saudi Arabia 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 376: UAE Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 377: UAE Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 378: UAE 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 379: UAE Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 380: UAE Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 381: UAE 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 382: UAE Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 383: UAE Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 384: UAE 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 385: UAE Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 386: UAE Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 387: UAE 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 388: Rest of Middle East Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 389: Rest of Middle East Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 390: Rest of Middle East 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 391: Rest of Middle East Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 392: Rest of Middle East Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 393: Rest of Middle East 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 394: Rest of Middle East Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 395: Rest of Middle East Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 396: Rest of Middle East 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 397: Rest of Middle East Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 398: Rest of Middle East Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 399: Rest of Middle East 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 400: Africa Current & Future Analysis for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 401: Africa Historic Review for Molecular Cytogenetics by Product & Service - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 402: Africa 15-Year Perspective for Molecular Cytogenetics by Product & Service - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2012, 2020 & 2027
    • TABLE 403: Africa Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 404: Africa Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 405: Africa 15-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Sales for CGH, FISH, Karyotyping, Immunohistochemistry and Other Techniques for the Years 2012, 2020 & 2027
    • TABLE 406: Africa Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 407: Africa Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 408: Africa 15-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
    • TABLE 409: Africa Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 410: Africa Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 411: Africa 15-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Sales for Clinical & Research Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 27
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.